Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for camrelizumab-induced reactive capillary hemangioma (RCCEP)
ChiCTR2600121980Phase 2Recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Capillary Haemangioma, bronchial carcinoma, esophageal cancer and 1 more, sponsored by Tianjin First Central Hospital. Primary endpoint: Median duration of RCCEP (from onset to resolution). Started Apr 2026; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Capillary Haemangiomabronchial carcinomaesophageal cancernasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600121980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121980.